BiotechTube

HSK31858 + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma Bronchiale

Conditions

Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)

Trial Timeline

Dec 10, 2024 → Jun 22, 2026

NCT ID
NCT06820749

About HSK31858 + Placebo

HSK31858 + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Asthma Bronchiale. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06820749. Target conditions include Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD).

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06820749Phase 2Recruiting
NCT06637254Phase 2Recruiting
NCT05601778Phase 2Completed

Competing Products

20 competing products in Asthma Bronchiale

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
77
DuleraMerckApproved
85
BriquilimabJasper TherapeuticsPhase 1
25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
52
RoflumilastAstraZenecaPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
52
Regadenoson + PlaceboAstellas PharmaApproved
85
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
77
rabeprazoleEisaiPhase 3
77
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
Placebo + BrodalumabKyowa KirinPhase 2
52
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
52
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved
82
Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved
82
Cyclopofol + PropofolApproved
82
Ciprofol + PropofolApproved
82
CipepofolApproved
82